Department of Cardiology, London Chest Hospital, Bonner Road, Bethnal Green, London E2 9JX, UK.
Heart. 2012 Nov;98(22):1626-31. doi: 10.1136/heartjnl-2011-301540. Epub 2012 Sep 2.
The rapid translation from bench to bedside that has been seen in the application of regenerative medicine to cardiology has led to exciting new advances in our understanding of some of the fundamental mechanisms related to human biology. The first generation of cells used in phase I-II trials (mainly bone marrow mononuclear cells) are now entering phase III clinical trials with the goal of producing a cell based therapeutic that can change the outcome of cardiac disease. First generation cell therapy appears to have addressed safety concerns as well as showing 'activity' in numerous published meta- analyses. With the knowledge gained to date, the field is moving towards the next generation of cells-the 'engineered' cell-that have been developed to display a phenotype that will further enhance the myocardial repair/salvage process. This almanac review covers the latest basic research that may soon have application to humans as well as the results of the latest clinical trials.
从基础研究到临床应用的快速转化在心脏病学中的再生医学应用中已经取得了令人兴奋的新进展，使我们对一些与人类生物学相关的基本机制有了更深入的了解。在 I 期和 II 期临床试验中使用的第一代细胞（主要是骨髓单个核细胞）目前正在进入 III 期临床试验，目的是开发一种基于细胞的治疗方法，从而改变心脏病的结局。第一代细胞治疗似乎已经解决了安全性问题，并在许多已发表的荟萃分析中显示出“疗效”。有了迄今为止获得的知识，该领域正在向新一代细胞——“工程细胞”发展，这些细胞经过设计，具有增强心肌修复/挽救过程的表型。本综述涵盖了最新的基础研究，这些研究可能很快就会应用于人类，以及最新临床试验的结果。
